Zealand Pharma Current Ratio 2017-2021 | ZEAL

Zealand Pharma current ratio from 2017 to 2021. Current ratio can be defined as a liquidity ratio that measures a company's ability to pay short-term obligations.
Zealand Pharma Current Ratio Historical Data
Date Current Assets Current Liabilities Current Ratio
2021-06-30 $0.26B $0.06B 4.19
2021-03-31 $0.30B $0.06B 5.18
2020-12-31 $0.22B $0.05B 4.00
2020-09-30 $0.27B $0.05B 5.81
2020-06-30 $0.29B $0.04B 6.76
2020-03-31 $0.20B $0.03B 7.30
2019-12-31 $0.21B $0.03B 7.31
2019-09-30 $0.24B $0.05B 5.18
2019-06-30 $0.18B $0.04B 4.48
2019-03-31 $0.20B $0.04B 4.86
2018-12-31 $0.19B $0.02B 11.05
2018-09-30 $0.23B $0.04B 5.30
2018-06-30 $0.08B $0.01B 7.82
2018-03-31 $0.10B $0.01B 11.17
2017-12-31 $0.11B $0.01B 9.28
2017-09-30 $0.13B $0.01B 12.63
2017-06-30 $0.05B $0.01B 6.39
2017-03-31 $0.07B $0.01B 4.81
2016-12-31 $0.06B $0.01B 4.26
Sector Industry Market Cap Revenue
Medical Medical - Biomedical and Genetics $1.407B $0.054B
Zealand Pharma A/S is a biotechnology company. It focused on the discovery, design and development of peptide-based medicines. Zealand Pharma A/S is based in Copenhagen, Denmark.
Stock Name Country Market Cap PE Ratio
Bristol Myers Squibb (BMY) United States $127.994B 8.52
Bio-Rad Laboratories (BIO.B) United States $21.730B 46.31
QIAGEN (QGEN) Netherlands $12.309B 20.85
Biohaven Pharmaceutical Holding (BHVN) United States $9.150B 0.00
Emergent Biosolutions (EBS) United States $2.677B 6.46
Arcus Biosciences (RCUS) United States $2.522B 0.00
Myovant Sciences (MYOV) United Kingdom $1.905B 0.00
ADC Therapeutics SA (ADCT) Switzerland $1.799B 0.00
Zymeworks (ZYME) Canada $1.071B 0.00
Ambrx Biopharma (AMAM) United States $0.474B 0.00
SQZ Biotechnologies (SQZ) United States $0.341B 0.00
Enzo Biochem (ENZ) United States $0.160B 15.76